Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia

Objectives: To describe the implementation of a new model face to face and remote pharmaceutical care with home delivery of tyronsine kinase inhibitors medicines for patients with chronic myeloid leukemia. Methods: Patients with chronic myeloid leukemia were selected to start this new model of care....

Full description

Saved in:

Bibliographic Details
Main Authors:	Begoña San José Ruiz, María Angeles Gil Lemus, María Puy Figuero Echeverria
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	Farmacia Hospitalaria
Subjects:	Leukemia Myelogenous Chronic BCR-ABL Positive Protein Kinase Inhibitors Patient-Centered Care Telemedicine
Online Access:	http://www.aulamedica.es/fh/pdf/7860.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 BCR::ABL1 fusion transcripts: a case report and review of the literature
by: Yang Xu, et al.
Published: (2024-12-01)

Coexistence of P190 BCR/ABL transcript and CALR 52-bp deletion in chronic myeloid leukemia blast crisis: a case report
by: najmaldin saki, et al.
Published: (2016-01-01)

Novel targeted therapies in chronic myeloid leukemia
by: Muhammad Sameer Ashaq, et al.
Published: (2024-12-01)

Hematological profile and its correlation with reverse transcription–polymerase chain reaction-based serial quantitative detection of BCR-ABL in chronic myeloid leukemia patients at a referral cancer center
by: Vanita Pandey, et al.
Published: (2024-12-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: Kotlyarchuk K., et al.
Published: (2015-09-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: K. Kotlyarchuk, et al.
Published: (2015-09-01)

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
by: Valentin Garcia-Gutierrez, et al.
Published: (2024-11-01)

Chronic myeloid leukemia in an asymptomatic young patient: a rare case report
by: Urja Bhatt, et al.
Published: (2024-11-01)

High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR‐ABL1‐like acute lymphoblastic leukemia
by: Jae Wook Lee, et al.
Published: (2020-07-01)

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
by: Zhen-Yu Xiong, et al.
Published: (2024-12-01)

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells
by: Masanobu Tsubaki, et al.
Published: (2025-01-01)

ACUTE MYELOID LEUKEMIA PRESENTING AS ACUTE PANCREATITIS WITH MULTISYSTEM LEUKEMIC INFILTRATION: A CASE REPORT OF PANCREATIC, BILIARY TRACT AND PULMONARY INVOLVEMENT
by: Yusuf Hekimoğlu, et al.
Published: (2024-12-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches
by: Dilinazi Abulaiti, et al.
Published: (2024-12-01)

Molecular cloning of EZH2 oncogene in chronic myeloid leukemia and therapeutic prospects
by: Juliana Costa Gaspar, et al.
Published: (2015-07-01)

Acute myelogenous leukemia revealed by acute appendicitis
by: Sanae El Marzguioui, et al.
Published: (2020-01-01)

Corrigendum: Dogs with acute myeloid leukemia have clonal rearrangements in T and B cell receptors
by: Tracy Stokol, et al.
Published: (2025-01-01)

NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
by: Gianfranco Catalano, et al.
Published: (2020-10-01)

T315I – a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia
by: Kaleem Bushra, et al.
Published: (2024-09-01)

COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity
by: Na He, et al.
Published: (2024-11-01)

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
by: Junichiro Yuda, et al.
Published: (2023-02-01)

Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients
by: Xueting Hou, et al.
Published: (2025-01-01)

REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION
by: Ivan Tonev, et al.
Published: (2025-01-01)

Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment
by: Yi-gang Guo, et al.
Published: (2024-12-01)

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01)

Gleevec耐受的发生机制与克服策略
by: 潘景轩
Published: (2011-01-01)

Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia
by: Aytan Shirinova
Published: (2024-03-01)

Designing a Neural Observer to Estimate the State Variables of the Dynamical System of a Specific Class of Leukaemia
by: Yousef Farshidi, et al.
Published: (2022-09-01)

Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction
by: Huijun Mu, et al.
Published: (2024-12-01)

Impacto de la mutación T315I en el pronóstico de la leucemia mieloide crónica
by: Kaleem Bushra, et al.
Published: (2024-11-01)

Chronic myeloid leukemia with involvement of membranous labyrinth
by: Mobachir El Kettani, et al.
Published: (2024-01-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Arterial Occlusive Events in a Patient With Chronic Myeloid Leukemia Treated With Ponatinib
by: Osamu Imataki, et al.
Published: (2024-11-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India
by: Sangita A. Vanik, et al.
Published: (2023-07-01)

SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection
by: Elisabetta Abruzzese, et al.
Published: (2020-04-01)

INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
by: Caterina Giovanna Valentini, et al.
Published: (2011-12-01)

INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
by: Morena Caira, et al.
Published: (2011-01-01)